Product image of Medimibi (Tetrafluoroborate) supplied by GNH India

Medimibi

Active Ingredient:
Tetrafluoroborate
Origin:
EU

Medimibi (Tetrafluoroborate)

Tetrafluoroborate, the active ingredient in Medimibi, is a chemical compound presented as an investigational formulation for intravenous use. It has not been assigned a specific therapeutic class and is not currently approved for a defined indication.

GNH India supplies Medimibi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Radiopharmacy Laboratórium Kft.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Medimibi (tetrafluoroborate) is currently not assigned to a specific therapeutic pathway and has no established clinical indications.

  • No approved clinical indications: currently not indicated for therapeutic use.

How It Works

  • The precise pharmacological mechanism of tetrafluoroborate when administered intravenously has not been publicly disclosed. Available data suggest it may interact with cellular ion channels or biochemical pathways, but detailed target information remains unavailable.

Side Effects

Adverse reaction information for Medimibi (tetrafluoroborate) is limited, and reported side effects are not well characterized.

Common Side Effects

  • Limited data: no common adverse events have been documented.

Serious or Rare Side Effects

  • Limited data: serious or rare adverse events have not been reported.

Precautions & Warnings

When handling Medimibi (tetrafluoroborate), standard precautions for intravenous agents should be observed.

  • Medical supervision: administration should be performed by qualified healthcare professionals.
  • Allergy assessment: verify patient has no known hypersensitivity to the product.
  • Monitoring: observe for any unexpected reactions during infusion.
  • Pregnancy and lactation: safety has not been established; use only if benefits outweigh risks.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Interaction data for tetrafluoroborate are scarce; potential drug interactions have not been systematically evaluated.

Major Interactions (Avoid)

  • No documented major interactions: insufficient evidence to define avoidance.

Moderate Interactions (Monitor Closely)

  • No documented moderate interactions: monitor patient response if co‑administered with other intravenous agents.

Frequently Asked Questions

Medimibi contains tetrafluoroborate and, as of current public information, does not have any approved therapeutic indication. It is considered an investigational compound and may be used in research settings under controlled conditions.

The exact mechanism of action of tetrafluoroborate when given intravenously has not been disclosed in publicly available literature. Preliminary data suggest possible interactions with cellular ion channels, but detailed pharmacodynamic pathways remain undefined.

Dosing for Medimibi is determined by the prescribing clinician based on the specific clinical context or research protocol. No standardized dose regimen is publicly documented.

Safety of tetrafluoroborate during pregnancy or lactation has not been established. It should only be used if the potential benefit justifies any possible risk to the mother or infant, and only under professional medical guidance.

To request Medimibi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and import documentation.

Because tetrafluoroborate does not have an established therapeutic class, there is no direct marketed alternative. Comparison is therefore limited to general pharmacological properties, which remain incompletely characterized in the public domain.

Medimibi should be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken. Follow all standard cold‑chain handling procedures to maintain product integrity.

Medimibi is supplied for intravenous administration. It must be infused by qualified healthcare professionals in a setting equipped for sterile IV delivery, following institutional protocols for infusion rate and monitoring.

Serious risks have not been fully defined due to limited clinical data. Healthcare providers should monitor patients closely for any unexpected infusion reactions, hemodynamic changes, or hypersensitivity signs during and after administration.

Patients with a known hypersensitivity to tetrafluoroborate or any component of the formulation should avoid its use. Additionally, use in pregnant or breastfeeding individuals is not recommended unless the potential benefit outweighs the risk.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Tetrafluoroborate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT